Cargo Therapeutics rises on Concentra Biosciences' buyout deal
View all comments(0)
Shares of drug developer Cargo Therapeutics CRGX.O up 9.6% at $4.81 premarket
Concentra Biosciences to buy CRGX in an all-cash deal valued at about $201.97 million
The offer values CRGX at $4.38 per share plus a non-transferable contingent value right (CVR)
CVR is tied to 80% of any net proceeds from certain drugs of CRGX's within two years of the deal and 100% of the closing net cash of co exceeding $217.5 million
The merger transaction is expected to close in August 2025 - CRGX
As of last close, stock down 69.56% YTD
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Like
Recommended Articles
Featured Tools
Top News
Why SanDisk Stock Could Soar to $4,000?

Is Micron the Next Nvidia? Why the 2026 "Memory Crunch" Makes MU Stock a Top AI Buy

AI Chip Sector Adds Heavyweight Player, Nvidia Rival Cerebras Plans to List Next Week, Targeting Largest US IPO of the Year

'Big Short' Burry Doubles Down: Nvidia, Palantir Short Positions Double in Big Bet on AI Bubble Bursting

Global First Storage ETF Surges 88% Five Weeks After Listing. Is It Too Late to Buy Now?

Tradingkey







Comments (0)
Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.